NCT05395845 is a EARLY_PHASE1 clinical trial of platelets rich plasma in Anosmia, sponsored by Aya abdelnasser hassani.

Who is sponsoring NCT05395845?

NCT05395845 is sponsored by Aya abdelnasser hassani.

What drugs are being tested in NCT05395845?

Interventions in NCT05395845: platelets rich plasma.

Is NCT05395845 still recruiting?

NCT05395845 is currently status unknown. Last updated 27 May 2022.

Last reviewed 2022-05-27 · How we verify

NCT05395845

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Value of Platelet-Rich Plasma in Post Severe Acute Respiratory Syndrome Coronavirus 2

Status unknown EARLY_PHASE1 Last updated 27 May 2022

What this trial tests

EARLY_PHASE1 trial testing platelets rich plasma in Anosmia in 88 participants. Status unknown.

Timeline

1 June 2022

Primary endpoint
1 December 2022

1 January 2023

Quick facts

Lead sponsor	Aya abdelnasser hassani
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	88
Start date	1 June 2022
Primary completion	1 December 2022
Estimated completion	1 January 2023

Drugs / interventions tested

platelets rich plasma — full drug profile →

Conditions studied

Anosmia — all drugs for Anosmia →

Sponsor

Aya abdelnasser hassani — full company profile →

Who can join

Adults 18 to 75, any sex, with Anosmia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will be conducted to evaluate : The efficacy of Platelet Rich plasma in treatment of smell disorders post severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via the growth factors involved in accelerating and enhancing healing.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Anosmia

Currently open trials in the same condition.

NCT06733636 — Scents of Progress: Leveraging a Novel Device for Olfactory Training in Older Adults · NA · recruiting
NCT05562050 — Characteristics of the Anosmic Olfactory Mucosa · active not recruiting
NCT05040659 — Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2 · active not recruiting
NCT05364125 — Olfactory Training on Smell Dysfunction Patients in HK · NA · recruiting
NCT06423495 — Efficacy of Photobiomodulation in the Rehabilitation of Olfactory Dysfunctions Induced by Long COVID-19 · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05395845 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aya abdelnasser hassani
Last refreshed: 27 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05395845.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing